Table 1.
Initial substudies planned in NCI-MATCH
| Agent(s) | Molecular target(s) | Estimated prevalence |
|---|---|---|
| Afatiniba | EGFR activating mutations | 1–4% |
| Afatiniba | HER2 activating mutations | 2–5% |
| Crizotinib | ALK rearrangement | 4% |
| AZD9291a | EGFR T790M mutations and rare EGFR activating mutations | 1–2% |
| Crizotinib | ROS1 translocations | 5% |
| Dabrafenib and Trametinib | BRAF V600E and V600K mutations | 7% |
| Trametinib | BRAF fusions or non-V600E, non-V600K BRAF mutations | 2.8% |
| TDM1a | HER2 amplification | 5% |
| VS-6063a | NF2 loss | 2% |
| Sunitiniba | cKIT mutations | 4% |
EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor type2; ALK, anaplastic lymphoma kinase; BRAF, v-Raf murine sarcoma viral oncogene homolog B.
aAgents and associated targets are pending final regulatory review.